Voxelotor

CHEMBL4101807 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
337.4 g/mol
LogP
2.7
Phase
4

Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that covalently and reversibly binds to the alpha-chain of hemoglobin, increasing hemoglobin oxygen affinity and stabilizing the oxygenated state to prevent HbS sickling and polymer formation in red blood cells. It is approved for sickle cell disease in patients aged 4 years and older to increase hemoglobin levels and reduce hemolysis. By preventing red blood cell sickling, it improves anemia and reduces vaso-occlusive complications.

分子量

337.4000 g/mol

LogP

2.70

TPSA

77.20 Ų

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O

InChI

InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3

Molecular Formula

C19H19N3O3

HBD / HBA

1 / 5

回転可能結合数

6

重原子数

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that covalently and reversibly binds to the alpha-chain of hemoglobin, increasing hemoglobin oxygen affinity and stabilizing the oxygenated state to prevent HbS sickling and polymer formation in red blood cells. It is approved for sickle cell disease in patients aged 4 years and older to increase hemoglobin levels and reduce hemolysis. By preventing red blood cell sickling, it improves anemia and reduces vaso-occlusive complications.

Yes, Voxelotor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4101807. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71602803. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.